NUR 635 Topic 4 respiratory therapy plan example

Advanced Pharmacology Grand Canyon University Free custom sample in 24 to 48h

This NUR 635 Topic 4 sample paper revises the COPD therapy of Mrs. V., a composite 72-year-old whose peak inspiratory flow of 32 liters a minute is too low for either prescribed dry powder inhaler. It was prepared for GCU NUR 635, Advanced Pharmacology, catalog code NUR-635, a core course of Grand Canyon University's MSN. Control is judged with stated measures. Controllers and the reliever are kept distinct by role. The long-acting bronchodilators move to a jet nebulizer with revefenacin, after Mahler, and the inhaled steroid is withdrawn under GOLD guidance. Teaching is written as steps, since Sanchis and colleagues found errors persist. Criteria for stepping up and down and a three-zone action plan close the plan.

CourseNUR 635 Advanced Pharmacology
TopicTopic 4
Paper typeRespiratory therapy plan
LengthAbout 990 words, 4 pages
FormatAPA 7 student paper
SchoolGrand Canyon University (GCU)
ProgramMSN
UpdatedOctober 2026

Free sample paper for NUR 635 Topic 4

1

Thirty-Two Liters a Minute: A COPD Therapy Plan That Moves a 72-Year-Old Woman From Dry Powder Inhalers to a Nebulizer and Off Her Inhaled Steroid

[Author Name]

College of Nursing and Health Care Professions, Grand Canyon University

NUR-635: Advanced Pharmacology

Topic 4 Assignment

[Instructor Name]

February 4, 2030

The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.

What this page is doingThe title leads with the measurement that decided the device, which makes the point that the delivery method is part of the prescription. The patient is a composite written for teaching.
2

Thirty-Two Liters a Minute: A COPD Therapy Plan That Moves a 72-Year-Old Woman From Dry Powder Inhalers to a Nebulizer and Off Her Inhaled Steroid

The Condition, Its Control and How Control Was Judged

Mrs. V., a composite 72-year-old woman, has chronic obstructive pulmonary disease with a forced expiratory volume in 1 second of 34 percent of predicted. She takes fluticasone-salmeterol 250/50 by dry powder inhaler twice daily, tiotropium 18 mcg by capsule dry powder inhaler once daily and albuterol by metered dose inhaler as needed. Three months ago she was admitted with an exacerbation complicated by pneumonia. Control was judged on four things rather than on her report alone: a COPD Assessment Test score of 24, breathlessness on walking 100 yards, albuterol use on most days, averaging eight puffs a day, and one exacerbation requiring admission in the past year. Her blood eosinophil count is 90 cells per microliter. Watching her use each device showed that she inhales steadily and slowly through both dry powder inhalers and does not hold her breath afterward. Peak inspiratory flow, measured with a handheld meter set to simulate each device's resistance, was 32 L/min against the capsule inhaler and 41 L/min against the other dry powder device. Dry powder devices need a fast, forceful inhalation to break the powder into particles small enough to reach the lower airways, and an optimal flow is at least 60 L/min (Mahler, 2017). Her control is poor, and her devices are part of the reason.

What this page is doingControl is judged from stated evidence, and the device check is part of the assessment. The inspiratory flow measurement explains why a correctly prescribed drug may not be reaching her airways.
3

The Agents by Role

Controllers are taken every day to keep airways open and prevent exacerbations; the reliever is taken only for symptoms. Her plan keeps them distinct. Controllers: revefenacin 175 mcg, a long-acting muscarinic antagonist, once daily, and arformoterol 15 mcg, a long-acting beta agonist, twice daily, both by nebulizer. Reliever: albuterol 2 puffs by metered dose inhaler with a valved holding chamber, up to every 4 hours as needed. A patient who needs the reliever on most days is telling the prescriber that her controllers are not working, and that is how her current albuterol use is read.

The inhaled corticosteroid is stopped. In chronic obstructive pulmonary disease, inhaled corticosteroids reduce exacerbations mainly in patients with higher blood eosinophil counts; with a count below 100, the expected benefit is small, and the risk of pneumonia, which she has just had, is real (Global Initiative for Chronic Obstructive Lung Disease [GOLD], 2024). This is the step down in her plan.

Each Agent Matched to a Device She Can Use

Because her inspiratory flow is too low for either dry powder device, the long-acting bronchodilators move to a jet nebulizer, which delivers drug during ordinary tidal breathing and does not depend on how hard she can inhale. In patients with suboptimal inspiratory flow, nebulized revefenacin did not significantly outperform the capsule dry powder inhaler overall but increased trough lung function in those with more severe obstruction, the group to which she belongs (Mahler et al., 2019). A soft mist inhaler was considered and declined because she would still need to coordinate pressing the device with a slow inhalation, which she found difficult on trial. The reliever stays as a metered dose inhaler because it is quick in an emergency, but with a valved holding chamber, which removes the need to time the puff to the breath.

What this page is doingThe device is chosen from a measurement and a trial, not from habit. The highlighted sentence gives the reason for the change in one line, and the alternatives considered are named with why they were declined.
4

Teaching, Written as Steps

Errors in inhaler use are common and have not improved over the decades they have been studied (Sanchis et al., 2016), so each device's teaching is written out, demonstrated and then watched as she does it back.

Nebulizer, for each dose: wash hands; twist open one vial and squeeze all of it into the cup; do not mix revefenacin with arformoterol, because they are given as separate treatments; attach the mouthpiece rather than a mask, so that the anticholinergic mist does not reach her eyes; sit upright, seal her lips around the mouthpiece and breathe normally through her mouth until the mist stops and the cup sputters, about 8 minutes; then rinse the cup and mouthpiece in warm water and let them air dry. She will know it worked if the cup is empty and her breathing is easier within 15 to 20 minutes.

Albuterol with the chamber: shake the inhaler; fit it to the chamber; breathe out gently away from the mouthpiece; seal her lips around it; press the canister once; breathe in slowly and deeply, or take four to six normal breaths if a deep breath is hard; wait 30 seconds and repeat for the second puff. If the chamber whistles, she is breathing in too fast. Relief should begin within 5 to 10 minutes. She will mark each use on a calendar.

Criteria for Stepping Up and Stepping Down

Step up if, after eight weeks on the new regimen with technique confirmed at a visit, she still uses albuterol on more than two days a week or has a moderate or severe exacerbation. Adding the inhaled corticosteroid back would then be reconsidered if her eosinophil count has risen to 100 or more, and pulmonary rehabilitation, already offered, would be pressed. Step down in device as well as in drug: inspiratory flow is often lower in the weeks after an exacerbation, so it will be measured again at eight weeks. If it reaches 60 L/min against a dry powder device, a once-daily handheld combination inhaler would replace the nebulizer, which takes more time each day.

Her Action Plan

Green, a usual day: nebulizer treatments on schedule and albuterol only if needed. Yellow, more breathless than usual, or sputum more in amount or changed in color for more than a day: take albuterol up to every 4 hours, start the prednisone course kept at home, and call the clinic the same day. Red, too breathless to speak in sentences, confusion, drowsiness or blue lips: call 911. Her husband has a copy on the refrigerator and was present for the teaching.

References

Global Initiative for Chronic Obstructive Lung Disease. (2024). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2024 report.

Mahler, D. A. (2017). Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Annals of the American Thoracic Society, 14(7), 1103-1107. https://doi.org/10.1513/AnnalsATS.201702-156PS

Mahler, D. A., Ohar, J. A., Barnes, C. N., Moran, E. J., Pendyala, S., & Crater, G. D. (2019). Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory flow rate. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, 6(4), 321-331. https://doi.org/10.15326/jcopdf.6.4.2019.0137

Sanchis, J., Gich, I., & Pedersen, S. (2016). Systematic review of errors in inhaler use: Has patient technique improved over time? Chest, 150(2), 394-406. https://doi.org/10.1016/j.chest.2016.03.041

What the NUR 635 Topic 4 instructions ask for

Topic 4 in NUR-635 asks students to build a therapy plan for a chronic respiratory condition. Strong plans state how control was judged and with what measures, separate controllers from relievers by role and match each agent to a device the patient can actually use, since a correct drug delivered badly reaches little of the airway. Students should justify any change in device with an objective measure, such as inspiratory flow, write teaching as steps the patient can follow and observe, and give criteria for stepping therapy up and down. The plan should end with an action plan in the patient's own terms, stating what to do on a usual day, a worse day and an emergency day, and should reference current guideline recommendations for withdrawing any agent.

How the NUR-635 Topic 4 example is put together

The finished example treats the device as part of the prescription. Each agent is matched to a delivery method chosen for this patient, since an inhaler requiring coordination will fail in some hands and a spacer or a different device solves it. Controller and reliever roles are kept distinct, with the example explicit that a patient relying on the reliever is a patient whose control has failed rather than one using their medication correctly. Stepwise adjustment appears with the criteria for stepping up and, unusually, for stepping down. Teaching is specific: what to do, in what order, how to know it worked, and what to check. Rinsing, technique verification and an action plan all appear as parts of the prescription.

Reading the NUR 635 Topic 4 rubric

Faculty reward each drug matched to a device the patient can use. An Excellent plan judges control with stated measures and keeps controllers and the reliever distinct. Credit goes to moving long-acting bronchodilators to a nebulizer because inspiratory flow is 32 liters a minute, citing Mahler and colleagues. The rubric values withdrawing the inhaled steroid under GOLD guidance. Strong plans write teaching as steps, since Sanchis and colleagues found errors persist. Top marks go to step criteria and a three-zone action plan in the patient's words.

Common NUR 635 Topic 4 mistakes, and how to avoid them

Prescriptions written without any teaching attached are the shortfall this topic exists to correct, since technique determines whether an inhaled drug reaches the airway at all. A second weakness is a device chosen without reference to the patient, where a metered dose inhaler requiring precise coordination is prescribed to somebody who will not manage it. Papers lose marks for blurring controller and reliever roles, which is the misunderstanding behind a great deal of poor control. Stepwise plans that never step down leave patients overtreated. Education described as provided, with no content, cannot be assessed and is the version that appears most often in student plans. Adherence problems attributed to the patient, where the device was never verified, misplace the cause entirely.

Get an NUR-635 Topic 4 example written to your instructions

Send the NUR-635 Topic 4 instructions and the rubric from your classroom, with the patient and condition your section assigned. We write a custom example to those criteria, with each agent matched to a device the patient can use, teaching written as steps and criteria given for stepping therapy both up and down, in 24 to 48 hours. The first is free.

More NUR 635 papers and MSN samples

NUR 635 Topic 4 questions, answered

Why does device choice matter as much as drug choice?

Because a correctly chosen drug delivered badly reaches very little of the airway. Devices differ in the coordination, the inspiratory effort and the dexterity they demand, and a patient who cannot manage the one prescribed is effectively untreated while appearing adherent. Matching the device to the person, and verifying technique rather than assuming it, is where much of the achievable benefit in respiratory prescribing actually sits.

How do I know when to step therapy down?

When control has been maintained for a sustained period at the current level, which most guidelines define in months rather than weeks. Stepping down is as much a part of the plan as stepping up, and omitting it leaves patients on treatment they no longer need with the side effects that carries. State the interval of good control you would require and what you would reduce first.

What belongs in an action plan?

What the patient does when symptoms change, expressed in their terms rather than in clinical thresholds. Which symptoms mean take the reliever, which mean start something additional or increase a dose, and which mean seek care the same day. Written plans work better than verbal ones, and giving the patient something they can hold is part of the prescription rather than an addition to it.

Where can I find a free NUR 635 Topic 4 sample paper?

The plan for NUR 635 Topic 4 covers control and how it was judged, agents by role, each agent matched to a device, teaching written as steps, criteria for stepping up and down and the action plan. Your own NUR 635 Topic 4 prompt gets a free paper.

Why stop the inhaled steroid in NUR 635 Topic 4?

Because GOLD guidance supports withdrawing it in patients without frequent exacerbations or raised eosinophils, where its pneumonia risk outweighs the benefit.